ClinicalTrials.gg
RecruitingNCT06776965NUTRIRICUpdated Apr 11, 2025

Ultra Processed Foods Consumption and Impact in Rheumatic Diseases.

An observational study in Rheumatoid Arthritis, Spondyloarthritis and Osteoarthritis, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 357 studies in Arthritis, Rheumatoid with a site in France — 42 open to participants now, 62 under way, 6 of them phase 3. Arthritis, Rheumatoid · France.

Planned enrollment
72nd of 134
240 · median 271
Started
2025
with 17 others
Observational
135 of 357
19 open now
Primary completion
2026-03
later than 12 of 61 live
Registered
337th of 357
by date

Among the 357 studies in Arthritis, Rheumatoid with a site in France, this one is the 72nd largest by planned enrollment of the 134 observational ones that give a count, is one of 18 that started in 2025, is one of 135 observational ones, reaches primary completion later than 12 of the 61 other live ones, and was the 337th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

42 of the 357 studies in Arthritis, Rheumatoid with a site in France are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 357 studies in Arthritis, Rheumatoid with a site in France, or all of them as a file.
02

Study summary

Ultra-processed foods (UPF) represent one of the mainstays of today's diet. They are defined by the NOVA classification system. It was demonstrated that UPF consumption was associated with activity of inflammatory bowel diseases with underlying mechanisms not fully identified yet. It is suspected that UPF constituents could modify the gut microbiota, increase intestinal barrier permeability and directly engage immune surveillance systems, effects that could individually or synergistically increase the risk of immunomediated diseases. As some pathophysiological mechanisms are shared among IBD and rheumatic diseases, we have wondered if UPF consumption could be associated with increased risk of rheumatic disease and/or with their activity.

Our primary aim will be to study the pattern of UPF consumption in patients with rheumatic diseases. Our secondary objectives will be to study the activity of diseases according to UPF consumption.

03

Conditions studied

  • Rheumatoid Arthritis
  • Spondyloarthritis
  • Osteoarthritis

Keywords

  • Ultra-processed food
  • osteoarthritis
  • rheumatoid arthritis
  • spondyloarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic rheumatological diseases (spondylitis, rheumatoid arthritis, osteoarthritis) and control population (also followed for any other pathology in the department).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • chronic rheumatic disease (Rheumatoid arthritis, spondyloarthritis, osteoarthritis)
  • ability to perform questionnaires

Exclusion criteria

Exclusion Criteria:

  • Judicial protection measure
  • Refusal to participate in the study
  • Suffering from 2 rheumatic disease simultaneously
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Rheumatoid Arthritis

    Patients in the first group will correspond to those with rheumatoid arthritis according to ACR criteria of RA

    Other: Dietary Questionnaire · Other: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)

  • Spondyloarthritis

    Patients in the second group will correspond to those with spondyloarthritis according ASDAS criteria

    Other: Dietary Questionnaire · Other: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)

  • Osteoarthritis

    Patients in the third group will correspond to those with spondyloarthritis according ACR criteria

    Other: Dietary Questionnaire · Other: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)

  • Controls

    Patients without rheumatic disease

    Other: Dietary Questionnaire · Other: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)

Interventions

  • OtherDietary Questionnaire

    Self administered dietary questionnaire at baseline, 6 and 12 months.

  • OtherEvaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)

    Self administered questionnaire of disease activity at baseline, 6 and 12 months.

06

What researchers measure

Primary outcomes

  1. Describe the consumption of ultra-processed foods in patients with chronic inflammatory rheumatism

    Describes the consumption of ultra-processed foods in patients with chronic inflammatory rheumatism using a self-assessment questionnaire (Score UPF Nova Screener) completed at baseline, 6 and 12 months.

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 12 months after the start.

Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 12 months is below that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 15, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Nov 30, 2026
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06776965
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Mar 31, 2025
Primary completion
Mar 31, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Apr 11, 2025

Study contacts

Maxime AUROUX, MD
Contact
Maxime.auroux@chu-lyon.fr
+33472117479
Maxime AUROUX, MD
principal investigator · Edouard Herriot Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion